Comparative Pharmacology
Head-to-head clinical analysis: CHLOROMYCETIN HYDROCORTISONE versus EOHILIA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLOROMYCETIN HYDROCORTISONE versus EOHILIA.
CHLOROMYCETIN HYDROCORTISONE vs EOHILIA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Chloromycetin (chloramphenicol) is a bacteriostatic antibiotic that inhibits protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation. Hydrocortisone is a corticosteroid that suppresses inflammation by inhibiting phospholipase A2 and reducing prostaglandin and leukotriene synthesis.
EOHILIA (budesonide) is a corticosteroid with potent glucocorticoid activity and weak mineralocorticoid activity. It binds to the glucocorticoid receptor, leading to inhibition of inflammatory mediators such as cytokines and arachidonic acid metabolites, thereby reducing inflammation in the esophagus.
Apply 1-2 drops or a small amount (approximately 0.5 cm ribbon) into the affected eye(s) every 3-4 hours, or more frequently as needed. For severe infections, may be used every 2 hours. Not to exceed 6 times daily. Otic: Instill 3-4 drops into the affected ear(s) 2-3 times daily.
For adults: 0.5 mg/kg IV every 2 weeks, infused over 60 minutes. Maximum single dose: 40 mg.
None Documented
None Documented
Chloramphenicol: 1.5-4 hours in adults with normal hepatic function; prolonged to 3-7 hours in neonates and up to 15 hours in severe liver disease. Hydrocortisone: 1-2 hours.
Terminal elimination half-life is 52 hours (steady state reached after 10-12 days of daily dosing)
Renal: ~80-90% of chloramphenicol as inactive metabolites (glucuronide conjugate) and 5-10% unchanged. Biliary: <3% of unchanged drug. Fecal: minimal.
Renal (70% unchanged drug), fecal (12%) and biliary (5%)
Category D/X
Category C
Corticosteroid
Corticosteroid